Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting – Yahoo Finance

Five poster presentations to include preclinical data describing new T-cell reprogramming technology being incorporated in LYL119, Lyell’s next product candidate

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that five abstracts highlighting preclinical data on its product candidates and new genetic and epigenetic reprogramming technologies were accepted for presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place in Boston, Nov. 8 – Nov. 12, 2022. The new preclinical data includes an abstract describing the effects of c-Jun overexpression in combination with NR4A3 gene knockout to enhance the functional activity of ROR1 CAR T cells. The combination of these two genetic reprogramming technologies is being incorporated in Lyell’s new product candidate, LYL119, a second generation investigational ROR1 targeting CAR T-cell therapy.
“Our presence at SITC includes presentations of new preclinical data from both existing and new reprogramming technologies being deployed in our growing pipeline of therapeutic candidates for solid tumors,” stated Dr. Gary Lee, chief scientific officer at Lyell. “We look forward to sharing these preclinical findings on the potential of Lyell’s reprogramming technologies that are designed to address primary barriers to successful adoptive cell therapy in solid tumors in order to improve clinical responses in patients.”
All the presentations describe preclinical data demonstrating that genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in various modalities, including CAR T cells, tumor-infiltrating lymphocytes (TILs) and T-cell receptor (TCR) T cells. Two presentations will feature preclinical data from LYL845, Lyell’s autologous TIL product candidate enhanced with Epi-R™ reprogramming technology, designed to create products with higher proportions of stem-like T cells. Lyell will also present preclinical data from its new genetic reprogramming technology designed to further limit T cell exhaustion, as well as data on its new epigenetic reprogramming technology, Stim-R™, designed to generate a more potent T cell product by controlling delivery of activation molecules during T cell production.
Details on the five poster presentations are below:
NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo 
Category: Cellular therapies – Chimeric Antigen Receptors
Presentation Date, Time & Location: Thursday, Nov. 10, Poster Hall
Abstract No.: 243

Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-R™ technology, a programmable synthetic cell-signaling platform
Category: Cellular Therapies – Chimeric Antigen Receptors
Presentation Date, Time & Location: Friday, Nov. 11, Poster Hall
Abstract No.: 252

The Epi-R™ technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function 
Category: Cellular therapies – Non-CAR adoptive cell therapies
Presentation Date, Time & Location: Friday, Nov. 11, Poster Hall
Abstract No.: 340

The Epi-R™ technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity
Category: Cellular therapies – Non-CAR adoptive cell therapies
Presentation Date, Time & Location: Friday, Nov. 11, Poster Hall
Abstract No.: 370

Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-R™ genetic reprogramming technology
Category: Cellular therapies – Non-CAR Adoptive Cell therapies
Presentation Date, Time & Location: Friday, Nov. 11, Poster Hall
Abstract No.: 232

About Lyell Immunopharma, Inc.
Lyell is a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors. The Company is advancing a pipeline of therapies designed to address what it believes are the primary barriers that limit consistent, reliable and curative responses to adoptive T-cell therapy: T cell exhaustion and lack of durable stemness, which includes the ability to proliferate, persist and self-renew, as well as generate differentiated effector cell progenies to provide durable anti-tumor functionality. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop new medicines with improved, durable and potentially curative clinical outcomes. Lyell is based in South San Francisco, California with facilities in Seattle and Bothell, Washington. To learn more, please visit www.lyell.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell’s anticipated progress, business plans, business strategy and planned clinical trials; the growing pipeline and potential clinical benefits and therapeutic potential of Lyell’s product candidates; the potential of Lyell’s reprogramming technologies to overcome primary barriers to successful adoptive cell therapy in solid tumors to improve clinical responses in patients; the ability for LYL845 to create products with higher proportions of stem-like T cells; the ability for Lyell’s new genetic reprogramming technology to limit T cell exhaustion and for its new epigenetic reprogramming technology, Stim-R, to generate a more potent T-cell product; and other statements that are not historical fact. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: the effects of the COVID-19 pandemic; geopolitical instability; Lyell’s ability to submit planned INDs or initiate and execute clinical trials on the anticipated timelines, if at all; Lyell’s ability to manufacture and supply its product candidates for its clinical trials; the preclinical profiles of Lyell’s product candidates not translating in clinical trials; the potential for results from clinical trials to differ from preclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with Lyell’s product candidates; the significant uncertainty associated with Lyell’s product candidates ever receiving any regulatory approvals; Lyell’s ability to obtain, maintain or protect intellectual property rights related to its product candidates; implementation of Lyell’s strategic plans for its business and product candidates; Lyell’s reliance on GSK to advance the development of its NY-ESO-1 programs; the sufficiency of Lyell’s capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading “Risk Factors” in Lyell’s most recently filed periodic reports on Form 10-K and Form 10-Q and in Lyell’s future reports to be filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.
Contact:
Ellen Rose
Senior Vice President, Communications and Investor Relations
erose@lyell.com

Related Quotes
Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.
These three top-ranked, best-performing and well-managed funds can help you maximize your retirement portfolio returns.
The Dow Jones and other major indexes posted their second day of gains Tuesday after early signs of a weakening job market. Tesla (TSLA) CEO Elon Musk threw in the towel, agreeing to buy Twitter (TWTR) at the original offering price of 54.20 per share. The Dow Jones Industrial Average was up 2.4% in afternoon trading after paring some of…
The wirehouse has recently lost several big teams to its rivals and to the independent advisor sector.
(Bloomberg) — Twitter users woke up April 4 and found the words “Elon” and “Elon Musk” trending on the site — not because the world’s richest, most-followed businessman had caused a stir with his futuristic companies, but because he’d disclosed a major stake in Twitter Inc.Suddenly, Musk was Twitter’s largest individual shareholder, with more than 9% of the company, and speculation swirled about how he would influence the network’s future. He’d been frequently tweeting ideas for revamping the s
Mary Anderson was ahead of her time. She was also dreaming like an entrepreneur. And problem-solving like an inventor.
The deal is expected to close in Q1 of 2023 and is subject to approval by stockholders.
Restaurant Brands (QSR) gains from robust comparable sales, unit growth, solid performance of Tim Hortons and focus on its loyalty program.
The $1.2 billion sale of Poshmark to South Korean internet giant Naver Corp may have valued the resale platform much lower than its IPO price, but as Naver’s biggest acquisition to date, it’s still a large bet on consumers’ appetite for secondhand items.
As the U.S. inflation debate intensifies, the signals are getting murkier. For investors, this makes markets more skittish and day-to- day moves harder to predict, and makes Fed forecasting even more difficult than it already is. On Wednesday, the headline U.S. services ISM purchasing managers index reading for September was surprisingly strong, declining far less than expected to 56.7 from 56.9.
Investors must pay capital gains taxes on the income they make as a profit from selling investments or assets. The federal government taxes long-term capital gains at the rates of 0%, 15% and 20%, depending on filing status and income. … Continue reading → The post 2022 Capital Gains Tax Rates by State appeared first on SmartAsset Blog.
(Bloomberg) — For many stock traders, it felt just about right that the market would take a breather after the dramatic rally of the past couple of days.After a bounce that started around noon in New York and was attributed to a big options trade, the S&P 500 came back lower again. For a market plagued by fears about a recession and the Federal Reserve’s struggles to tame high inflation, the rebound from this year’s bottom has maybe gone too far, too fast.Fundamentally speaking, nothing has cha
The latest price moves in bitcoin (BTC) and crypto markets in context for Oct. 5, 2022. First Mover is CoinDesk’s daily newsletter that contextualizes the latest actions in the crypto markets.
The move to curb output will likely push up already-high global energy prices and help oil-exporting Russia pay for its war in Ukraine.
Netherlands-based fertilizers company OCI NV is expanding production of low-carbon "blue" ammonia from its facility near Beaumont, and KBR Inc. (NYSE: KBR) is providing technology and engineering services.
Universal life insurance policies provide flexibility – and a cash value portion.
The Swiss National Bank (SNB) is following the situation at Credit Suisse closely, SNB Governing Board member Andrea Maechler told Reuters on Wednesday. "We are monitoring the situation," Maechler said on the sidelines of an event in Zurich. The SNB has declined to comment in the past about Credit Suisse, which has said it has a strong capital base and liquidity.
The Reserve Bank of New Zealand raised its key interest rate by 50 basis points to 2.50% as expected by most economists surveyed by Bloomberg. Kathleen Hays reports on Bloomberg Television with David Ingles and Yvonne Man.
The shares just pulled back to the historically bearish 180-day moving average
(Bloomberg) — An investment firm backed by Carlyle Group Inc. co-founder David Rubenstein has raised money from some of the world’s super-rich, creating its first fund employing outside cash.Declaration Partners collected $240 million from wealthy individuals and family offices to target multifamily housing and industrial properties across the US, the New York-based company said in a statement. Rubenstein is also an investor in the vehicle.About half of the fund’s capital has already been commi

source